• Explore /
  • Poster
  • / Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Abstract Video & Slides Poster

Authors

Eric Small

Eric Jay Small

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

Eric Jay Small , Fred Saad , Simon Chowdhury , Stephane Oudard , Boris A. Hadaschik , Julie N Graff , David Olmos , Paul N. Mainwaring , Ji Youl Lee , Hiroji Uemura , Peter De Porre , Andressa Smith , Sabine Doris Brookman-May , Susan Li , Ke Zhang , Oliver Brendan Rooney , Angela Lopez-Gitlitz , Matthew Raymond Smith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01946204

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5516)

DOI

10.1200/JCO.2020.38.15_suppl.5516

Abstract #

5516

Poster Bd #

97

Abstract Disclosures

Similar Posters

First Author: Eric Jay Small

First Author: Tomasz M. Beer

First Author: Irbaz Bin Riaz

First Author: Felix Y Feng